I am a Clinician Scientist with a special interest in clinical and translational research in blood cancers, in particular multiple myeloma and am a member of the International Myeloma Working Group. My research interests include the role of glycosylation in the pathogenesis of multiple myeloma, immuno-oncology and drug development. Areas of current research in my lab include (1) understanding the interactions between selectins and their ligands in disease progression and resistance and development of novel therapeutic approaches to overcome these (2) role of small molecule inhibitors as therapeutic strategies (3) reversing immune tolerancesuppression in the tumor microenvironment (4) exploring novel approaches to NK cell therapy. There is a strong translational focus to my research which feeds into phase I clinical trials conducted through the HRB Clinical Research Facility at NUI Galway and the Blood Cancer Network, Ireland (BCNI). In addition to early phase studies I am actively involved in phase II and III industry sponsored studies. I am currently Chief Investigator on two phase I studies in Multiple Myelomaopen through BCNI.I am currently funded by Science Foundation Ireland, the Irish Cancer Society and the Health Research Board and have several active industry collaborations, including with Janssen, Celgene, Carrick Therapeutics, Glycomimetics andOnkimmune.